Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993873 · ClinicalTrials.gov registry record · Phase 1
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors, sponsored by Turning Point Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT03993873: Active Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors, sponsored by Turning Point Therapeutics.
NCT03993873 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors that is active but no longer recruiting, run by Turning Point Therapeutics. The registered enrollment target is 95 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03993873, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Turning Point Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)
Primary Outcome
Evaluate the safety and tolerability of elzovantinib
Conditions Studied
Interventions
- DRUG elzovantinib (TPX-0022)
Study Locations (20)
Other
- Local Institution - 4201 - Lyon
- Local Institution - 6304 - Seoul
- Local Institution - 6303 - Seoul
- Local Institution - 6302 - Seoul
California
- Local Institution - 2102 - La Jolla
- Local Institution - 2108 - Orange
Massachusetts
- Local Institution - 2107 - Boston
- Local Institution - 2109 - Boston
Michigan
- Local Institution - 2106 - Ann Arbor
- Local Institution - 2113 - Detroit
Val-de-Marne
- Local Institution - 4203 - Saint-Mandé
- Local Institution - 4204 - Villejuif
Colorado
- Local Institution - 2105 - Denver
Illinois
- Local Institution - 2111 - Chicago
Missouri
- Local Institution - 2103 - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2027-03-03 |
| Phase | Phase 1 |
What the registry record for NCT03993873 still lists
NCT03993873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (51% lower).
The record links to 3 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which elzovantinib (TPX-0022) is the first listed.
NCT03993873 names 20 study sites across 13 states, led by Other, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03993873 about?
NCT03993873 is a clinical study titled "Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET". A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)
What is the current status of trial NCT03993873?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2019-09-05. Estimated completion is 2027-03-03.
What conditions does trial NCT03993873 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations.
What interventions are being tested in trial NCT03993873?
The interventions under investigation include: elzovantinib (TPX-0022) (DRUG).
Who is sponsoring clinical trial NCT03993873?
This trial is sponsored by Turning Point Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03993873 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03993873's enrollment target sits among peer trials
95 120th of 189 higher than 69 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI